Related Experiment Videos
Moxalactam therapy of serious pediatric infections
Abstract:
Forty children with documented or suspected bacterial infections arising outside the central nervous system (CNS) were studied. Fifteen different pathogens for a total of 30 isolates were obtained from multiple sources. Staphylococcus aureus (minimum inhibitory concentrations 4-8 micrograms/ml) was the most common pathogen isolated, involving seven patients. Each patient received moxalactam 50 mg/kg iv over 15 minutes q8h and responded favorably to therapy, exhibiting bacteriologic and/or clinical cures. Toxicity associated with moxalactam occurred in only two patients and necessitated discontinuation of drug therapy. Moxalactam 50 mg/kg iv q8h is effective therapy for non-CNS infections occurring in infants and children.
Insights
Moxalactam effectively treated bacterial infections outside the central nervous system (CNS) in children. The antibiotic showed favorable outcomes with minimal toxicity, demonstrating its efficacy in pediatric patients.
Area of Science:
- Pediatric Infectious Diseases
- Bacterial Infections
- Antibiotic Therapy
Background:
- Bacterial infections outside the central nervous system (CNS) are common in children.
- Effective and safe antibiotic options are crucial for pediatric care.
- Staphylococcus aureus is a frequent cause of pediatric bacterial infections.
Purpose of the Study:
- To evaluate the efficacy and safety of moxalactam in treating non-CNS bacterial infections in children.
- To determine the clinical and bacteriologic cure rates associated with moxalactam therapy.
- To assess the incidence of adverse events during moxalactam treatment.
Main Methods:
- A study of forty children with documented or suspected non-CNS bacterial infections.
- Isolation and identification of causative pathogens, with Staphylococcus aureus being the most common.
- Administration of moxalactam at a dosage of 50 mg/kg intravenously every 8 hours.
Main Results:
- All patients receiving moxalactam showed favorable responses, achieving bacteriologic and/or clinical cures.
- Staphylococcus aureus was the most frequently isolated pathogen in seven patients.
- Adverse events were infrequent, with only two patients requiring discontinuation of moxalactam due to toxicity.
Conclusions:
- Moxalactam is an effective therapeutic agent for treating bacterial infections outside the CNS in pediatric patients.
- The favorable efficacy and low toxicity profile support the use of moxalactam in this population.
- Further research may explore moxalactam's role in a broader range of pediatric infections.